drugset / Trial / NCT07516093
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
RandomizedParallel-groupOpen-labelTreatment
Summary
The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.
Timeline
- Start
- 2026-06
- Primary completion
- 2029-10
- Completion
- 2032-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NX-5948 | Other / unclassified | — | Oral |
| Subject | Pirtobrutinib | Other / unclassified | — | Oral |